Xopenex

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2014
0119992014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
To understand how the Centers for Medicare and Medicaid Services (CMS) approaches its responsibilities regarding the coding… (More)
Is this relevant?
2009
2009
The committee developed these guidelines to reflect its stance that levalbuterol should be considered a second-line therapy to… (More)
  • table 1
  • figure 1
Is this relevant?
2006
2006
BACKGROUND Hydrofluoroalkane-propelled levalbuterol (Xopenex) aerosol is a recently approved formulation for delivery via metered… (More)
  • figure 1
  • table 1
Is this relevant?
2005
2005
Pleased with Sepracor’s 2004 results and its anticipated launch in the first quarter of 2005 of one of biotech’s rare mass-market… (More)
Is this relevant?
Review
2004
Review
2004
Effective asthma control requires long-term (anti-inflammatory) controller medications for patients with mild-persistent to… (More)
Is this relevant?
2002
2002
  • Nursing
  • 2002
 
Is this relevant?
1999
1999
BACKGROUND Limited dose-response information is available for nebulized beta2 -agonists, especially in young children… (More)
Is this relevant?